A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Participants
Information source: Janssen Research & Development, LLC
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Volunteers
Intervention: Pioglitazone HCl (Drug); Abiraterone acetate (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Janssen Research & Development, LLC Official(s) and/or principal investigator(s): Janssen Research & Development, LLC Clinical Trial, Study Director, Affiliation: Janssen Research & Development, LLC
Summary
The purpose of this study is to evaluate the effects of abiraterone on the pharmacokinetics
(study of what the body does to a drug) of pioglitazone when coadministered with abiraterone
acetate in healthy adult male participants.
Clinical Details
Official title: An Open-Label Drug-Drug Interaction Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Subjects
Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Maximum observed plasma concentration of pioglitazoneTime to reach the maximum observed plasma concentration of pioglitazone Area under the plasma concentration-time curve from time 0 to time of the last observed quantifiable concentration of pioglitazone Area under the plasma concentration-time curve from time 0 to infinite time of pioglitazone Percentage of area under the plasma concentration time curve obtained by extrapolation of pioglitazone Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of pioglitazone Time to last observed quantifiable plasma concentration of pioglitazone
Secondary outcome: Maximum observed plasma concentration of abirateroneTime to reach the maximum observed plasma concentration of abiraterone Area under the plasma concentration-time curve from time 0 to time of the last observed quantifiable concentration of abiraterone Area under the plasma concentration-time curve from time 0 to infinite time of abiraterone Percentage of area under the plasma concentration-time curve obtained by extrapolation of abiraterone Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of abiraterone Time to last observed quantifiable plasma concentration of abiraterone Apparent total plasma clearance of drug after extravascular administration of pioglitazone Metabolite to parent drug ratio for maximum observed plasma concentration Metabolite to parent drug ratio for area under the plasma concentration time curve from time 0 to time of the last observed quantifiable concentration Metabolite to parent drug ratio for area under the plasma concentration time curve from time 0 to infinite time Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)
Detailed description:
This is an open-label (identity of assigned study drug will be known) single-dose drug-drug
interaction study to assess the effect of abiraterone on pioglitazone. Approximately 16
healthy adult male participants will be enrolled in this study. The study consists of a
screening phase, an open-label treatment phase consisting of 2 single-dose treatment
periods, end-of-study or withdrawal assessments done upon completion of the 72-hour
pharmacokinetic sampling on Day 11 of Period 2 or upon withdrawal, and a follow-up visit 5
to 7 days after the last study procedure. The total study length is 32 days. Participants
will receive pioglitazone alone on Day 1 (Period 1) of the study. On Day 8 (Period 2),
participants will receive a single dose of abiraterone acetate followed by a single dose of
pioglitazone one hour later. Successive pioglitazone administrations will be separated by a
washout period of 7 days. Participants will be confined to the study center from Day - 1 to
Day 4 of Period 1 and from Day 7 to Day 11 of Period 2, at least 10 hours before each study
drug administration until completion of the 72-hour blood sample collection for each period.
A pharmacogenomic blood sample will be collected from all participants on Day - 1. Safety
will be monitored throughout the study.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Agrees to protocol-defined use of effective contraception for 1 week after receiving
the last dose of study drug
- Agrees to not donate sperm during the study and for 1 week after receiving the last
dose of study drug
- Body mass index between 18 and 30 kg/m2 and body weight not less than 50 kg
- Blood pressure between 90 and 140 mmHg systolic, and no higher than 90 mmHg diastolic
- A 12-lead electrocardiogram consistent with normal cardiac conduction and function
- Non-smoker
- Laboratory values within protocol -defined parameters
Exclusion Criteria:
- History of or current clinically significant medical illness
- Clinically significant abnormal values for hematology, clinical chemistry, or
urinalysis at screening or at admission to the study center as deemed appropriate by
the investigator
- Presence of sexual dysfunction or any medical condition that would affect sexual
function
- Clinically significant abnormal physical examination, vital signs, or 12-lead
electrocardiogram
- Use of any prescription or nonprescription medication (including vitamins and herbal
supplements) before the first dose of the study drug is scheduled through study
completion
- History of drug or alcohol abuse within 3 years before screening or positive test
result(s) for alcohol and/or drugs of abuse at screening and Day - 1 and at Day 7 of
the treatment period
- Known allergy to the study drug or any of the excipients of the formulation
- History of stomach or intestinal surgery or resection that would potentially alter
absorption or excretion of orally administered drugs (appendectomy and hernia repair
will be allowed)
- Donated blood or blood products or had substantial loss of blood within 3 months
before the first administration of study drug or intention to donate blood or blood
products during the study
- Received an experimental drug or used an experimental medical device within 1 month
or within a period less than 10 times the drug's half-life, whichever is longer,
before the first dose of the study drug is scheduled
- Positive test for human immunodeficiency virus 1 and 2 antibodies, hepatitis B
surface antigen, hepatitis B core antibody or hepatitis C antibodies
- Preplanned surgery or procedures that would interfere with the conduct of the study
Locations and Contacts
Merksem, Belgium
Additional Information
Starting date: May 2013
Last updated: April 16, 2014
|